Qiagen N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
29 jul 2015 - 22:00
Statutaire naam
Qiagen N.V.
Titel
QIAGEN reports results for second quarter and first half of 2015
Bericht
• Q2 2015 results: Adjusted net sales of $319.5 million (+5% CER); adjusted operating income of $78.9 million; and adjusted EPS of $0.26 ($0.28 CER)
o Adjusted net sales rise 8% CER excluding reduced HPV sales in U.S.
o Growth drivers provide 32% of sales and advance at double-digit CER pace, leading the underlying strong and sustained business expansion
• H1 2015 results: Adjusted net sales of $618.1 million (+4% CER); adjusted operating income of $146.3 million; and adjusted EPS of $0.47 ($0.52 CER)
o Free cash flow up 10% to $84.1 million while supporting key investments
• QIAGEN reaffirms expectations for higher 2015 CER adjusted net sales and earnings; adverse impact on reported results from currency movements
Datum laatste update: 01 september 2024